Skip to main content

Table 4 Test characteristics of multiple algorithms among patients aged ≥ 65 y

From: An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: the influence of the reference standard on algorithm performance

Algorithms [Pretest prevalence: 1.8%]

TP

TN

FN

FP

Post-test prev.#

Sensitivity [95 CI%]

Specificity [95 CI%]

PPV [95 CI%]

NPV [95 CI%]

1 P AND ≥1 Rx ever

53

3248

10

115

4.9%

84 (75–93)

97 (96–97)

32 (25–39)

100 (100–100)

2 P AND ≥1 Rx ever

51

3318

12

45

2.8%

81 (71–91)

99 (98–99)

53 (43–63)

100 (99–100)

2 P ≥ 60 days apart AND ≥1 RX ever

49

3320

14

43

2.7%

78 (68–88)

99 (98–99)

53 (43–64)

100 (99–100)

(1 H ever) OR (2 P AND ≥1 Rx in 1 YR)

52

3337

11

26

2.3%

83 (73–92)

99 (99–100)

67 (56–77)

100 (100–100)

(1 H ever) OR (2 P AND ≥1 Rx in 2 YR)

52

3335

11

28

2.3%

83 (73–92)

99 (99–100)

65 (55–76)

100 (100–100)

(1 H ever) OR (2 P AND ≥1 RX in 3 YR)

52

3332

11

31

2.4%

83 (73–92)

99 (99–99)

63 (52–73)

100 (100–100)

(1 H ever) OR (2 P with ≥ 1 P by specialist AND ≥1 Rx in 1 YR)

52

3347

11

16

2.0%

83 (73–92)

100 (99–100)

77 (66–87)

100 (100–100)

(1 H ever) OR (2 P with ≥ 1 P by specialist AND ≥1 Rx in 2 YR)

52

3346

11

17

2.0%

83 (73–92)

100 (99–100)

75 (65–86)

100 (100–100)

(1 H ever) OR (2 P with ≥ 1 P by specialist AND ≥ 1 Rx in 3 YR)

52

3345

11

18

2.0%

83 (73–92)

100 (99–100)

74 (64–85)

100 (100–100)

(1 H ever) OR (3 P AND ≥ 1 Rx in 1 YR)

47

3346

16

17

1.9%

75 (64–85)

100 (99–100)

73 (63–84)

100 (99–100)

(1 H ever) OR (3 P AND ≥ 1 Rx in 2 YR)

48

3342

15

21

2.0%

76 (66–87)

99 (99–100)

70 (59–80)

100 (99–100)

(1 H ever) OR (3 P AND ≥ 1 Rx in 3 YR)

48

3342

15

21

2.0%

76 (66–87)

99 (99–100)

70 (59–80)

100 (99–100)

(1 H ever) OR (3 P with ≥ 1 P by specialist AND ≥ 1 Rx in 1 YR)

47

3351

16

12

1.7%

75 (64–85)

100 (99–100)

80 (69–90)

100 (99–100)

(1 H ever) OR (3 P with ≥ 1 P by specialist AND ≥ 1 Rx in 2 YR)

48

3349

15

14

1.8%

76 (66–87)

100 (99–100)

77 (67–88)

100 (99–100)

(1 H ever) OR (3 P with ≥ 1 P by specialist AND ≥ 1 Rx in 3 YR)

48

3348

15

15

1.8%

76 (66–87)

100 (99–100)

76 (66–87)

100 (99–100)

  1. Seniors 65+: N = 3426 patients (63 RA and 3363 non-RA); # = Post-test prevalence; TP = True Positive; TN = True Negative; FN = False Negative; FP = False Positive; H: Hospitalization code; P = physician diagnosis code; Specialist = rheumatologist, internal medicine, orthopedic surgeon; Rx refers to drug exposures: oral corticosteroid, disease-modifying anti-rheumatic drug (DMARD) or biologic; DMARDs included: Azathioprine, Chloroquine, Cyclophosphamide, Cyclosporine, Gold, Minocycline; and Biologics included: Etanercept, Adalimumab, Infliximab, Certolizumab, Golimumab; Abatacept, Anakinra, Rituximab, Tocilizumab.